Viatris recently presented an abstract on
Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress. Additionally, the company has reported its second quarter financial results for 2024. Despite earnings outpacing estimates, sales missed their mark. On a positive note, Viatris has completed all previously announced
divestitures with the closing of its over-the-counter business divestiture. There's been a relief from antitrust investigations as the U.S. Department of Justice no longer considers Viatris' subsidiary,
Mylan, a subject of interest in the generic drug industry. Encouragingly, Viatris was named to
TIME's Most Sustainable Companies 2024 list. However, the US FDA declined to approve Viatris's injection for multiple sclerosis. There's been insider selling reported, with Chief Legal Officer Brian Roman and President of Greater China Xiangyang Ni selling large quantities of shares.
Rogerio Vivaldi Coelho, M.D., has been appointed to the board of directors. Viatris has also published its 2023
Sustainability Report, emphasising its efforts in building sustainable access at scale and empowering healthcare workers.
Viatris VTRS News Analytics from Wed, 27 Sep 2023 07:00:00 GMT to Fri, 23 Aug 2024 10:59:00 GMT -
Rating -5
- Innovation 2
- Information 2
- Rumor -2
